Chronic Myeloproliferative Disorders Completed Phase 3 Trials for Ondansetron (DB00904)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006348Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer TreatmentSupportive Care